Solvent effects on activity and conformation of plasminogen activator inhibitor-1
- PMID: 10102470
Solvent effects on activity and conformation of plasminogen activator inhibitor-1
Abstract
We have studied effects of the solvent composition on the activity and the conformation of human plasminogen activator inhibitor-1 (PAI-1) from HT-1080 fibrosarcoma cells. Non-ionic detergents, includine Triton X-100, reduced the inhibitory activity of PAI-1 more than 20-fold at 0 degrees C, but less than 2-fold at 37 degrees C, while glycerol partly prevented the detergent-induced activity-loss at 0 degrees C. The activity-loss was associated with an increase in PAI-1 substrate behaviour. Evaluating the PAI-1 conformation by proteolytic susceptibility of specific peptide bonds, we found that the V8-proteinase susceptibility of the Glu332-Ser333 (P17-P16) bond, part of the hinge between the reactive centre loop (RCL) and beta-strand 5A, and the endoproteinase Asp-N susceptibility of several bonds in the beta-strand 2A-alpha-helix E region were increased by detergents at both 0 and 37 degrees C. The susceptibility of the Gin321-Ala322 and the Lys325-Val326 bonds in beta-strand 5A to papain and trypsin, respectively, was increased by detergents at 0 degrees C, but not at 37 degrees C, showing a strict correlation between proteinase susceptibility of beta-strand 5A and activity-loss at 0 degrees C. Since the beta-strand 2A-alpha-helix E region also showed differential susceptibility to endoproteinase Asp-N in latent, active, and reactive centre-cleaved PAI-1, we propose that a detergent-induced conformational change of the beta-strand 2A-alpha-helix E region influences the movements of beta-sheet A, resulting in a cold-induced conformational change of beta-strand 5A and thereby an increased substrate behaviour at low temperatures. These results provide new information about the structural basis for serpin substrate behaviour.
Similar articles
-
Conformational changes of the reactive-centre loop and beta-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1.Eur J Biochem. 1996 Oct 1;241(1):38-46. doi: 10.1111/j.1432-1033.1996.0038t.x. Eur J Biochem. 1996. PMID: 8898886
-
Vitronectin and substitution of a beta-strand 5A lysine residue potentiate activity-neutralization of PA inhibitor-1 by monoclonal antibodies against alpha-helix F.Thromb Haemost. 2000 May;83(5):742-51. Thromb Haemost. 2000. PMID: 10823273
-
Type-1 plasminogen-activator inhibitor -- conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility.Eur J Biochem. 1997 Sep 15;248(3):775-85. doi: 10.1111/j.1432-1033.1997.t01-1-00775.x. Eur J Biochem. 1997. PMID: 9342229
-
The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor type-1: roles of the reactive centre loop, the shutter region, the flexible joint region and the small serpin fragment.Biol Chem. 2002 Jan;383(1):21-36. doi: 10.1515/BC.2002.003. Biol Chem. 2002. PMID: 11928815 Review.
-
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.Biol Chem. 2002 Jul-Aug;383(7-8):1143-9. doi: 10.1515/BC.2002.125. Biol Chem. 2002. PMID: 12437099 Review.
Cited by
-
Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis.Thromb J. 2018 Jun 5;16:12. doi: 10.1186/s12959-018-0166-4. eCollection 2018. Thromb J. 2018. PMID: 29991926 Free PMC article.
-
Single fluorescence probes along the reactive center loop reveal site-specific changes during the latency transition of PAI-1.Protein Sci. 2016 Feb;25(2):487-98. doi: 10.1002/pro.2839. Epub 2015 Nov 25. Protein Sci. 2016. PMID: 26540464 Free PMC article.
-
Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.Front Cardiovasc Med. 2020 Dec 22;7:622473. doi: 10.3389/fcvm.2020.622473. eCollection 2020. Front Cardiovasc Med. 2020. PMID: 33415130 Free PMC article. Review.
-
Low Molecular Weight Antagonists of Plasminogen Activator Inhibitor-1: Therapeutic Potential in Cardiovascular Disease.Mol Med Ther. 2012 Aug 5;1(1):101. doi: 10.4172/2324-8769.1000102. Mol Med Ther. 2012. PMID: 23936868 Free PMC article.
-
Functional stability of plasminogen activator inhibitor-1.ScientificWorldJournal. 2014;2014:858293. doi: 10.1155/2014/858293. Epub 2014 Oct 15. ScientificWorldJournal. 2014. PMID: 25386620 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous